IMR Press / FBE / Volume 15 / Issue 1 / DOI: 10.31083/j.fbe1501005
Open Access Review
Is miR-223 Upregulation in Inflammatory Bowel Diseases a Protective Response?
Show Less
1 Research Department, Medlab Clinical, 2015 Sydney, Australia
2 Faculty of Medicine and Health, The University of Sydney, 2006 Sydney, Australia
*Correspondence: (Jiezhong Chen); (Luis Vitetta)
Front. Biosci. (Elite Ed) 2023, 15(1), 5;
Submitted: 24 June 2022 | Revised: 9 November 2022 | Accepted: 11 November 2022 | Published: 6 February 2023
(This article belongs to the Special Issue MicroRNAs and Other Non-coding RNAs in Human Health)
Copyright: © 2023 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.

Inflammatory bowel diseases (IBD) are characterized by chronic inflammation and damage of colonocytes with etiology of genetic, epigenetic and environmental factors. MicroRNA-223 (miR-223) has been found to be increased in both IBD patients and animal colitis models. However, contentious opinions relevant to the roles of miR-223 in IBD have been reported. Notwithstading that most studies have described that miR-223 has anti-inflammatory effects, several reports have progressed a pro-inflammatory view. In this review, we summarise both the anti-inflammatory and pro-inflammatory effects of miR-223 on key molecules in inflammatory responses in both animal models and in patients diagnosed with IBD and objectively discuss the possible basis for the discrepancies.

gut microbiota
Fig. 1.
Back to top